Treatment Comparison and AbbVie

Selected news for the healthcare topic - Treatment Comparison, and the company - AbbVie. We have a small number of shared news items for this connection to-date. Based on the volume of shared news, it's source, word placement and other factors, this connection is scored as preliminary.  Treatment Comparison shares news with Food and Drug Administration, AbbVie, National Institutes of Health and several others. AbbVie shares news with Allergan, Pfizer, Merck, Novartis, Bristol-Myers Squibb and hundreds of others.

Selected Headlines

Date Headline (link) Source Relevant Snippet
11/6/2019 Janssen to Present Latest Research from Robust Blood Cancer and Cardiovascular Disease Portfolios at this Year's American Society of Hematology Annual Meeting PR Newswire ... cell lymphoma (MCL). IMBRUVICA ® , a BTK inhibitor, is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. New XARELTO ® Data Focuses on Treating and Preventing Venous Thromboembolism (VTE) Across Many ... 7 5:30 p.m. – 7:30 p.m. ET Abstract 2142 An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible ...
11/6/2019 Janssen to Present Latest Research from Robust Blood Cancer and Cardiovascular Disease Portfolios at this Year's American Society of Hematology Annual Meeting | P&T Community ... cell lymphoma (MCL). IMBRUVICA ® , a BTK inhibitor, is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. New XARELTO ® Data Focuses on Treating and Preventing Venous Thromboembolism (VTE) Across Many ... 7 5:30 p.m. – 7:30 p.m. ET Abstract 2142 An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible ...
11/5/2019 Neurocrine Biosciences Inc (NBIX) Q3 2019 Earnings Call Transcript | The Motley Fool ... strong INGREZZA performance and included the recent NDA submission of elagolix for uterine fibroids, which was submitted by our partner, AbbVie. During the third quarter, INGREZZA prescription volume increased to approximately 34,800 scripts, resulting in ... of INGREZZA. In addition, in August, we published an indirect treatment comparison of valbenazine versus deutetrabenazine efficacy, using pool's clinical trial data, which demonstrated that valbenazine was generally favorable over deutetrabenazine, particularly at the 80 ...